Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

MedCap

521.00 SEK

-2.43 %

Less than 1K followers

MCAP

NASDAQ Stockholm

Investment

Financials

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-2.43 %
-4.58 %
-14.03 %
+18.14 %
-13.31 %
-11.99 %
+149.28 %
+134.68 %
+5,058.42 %

MedCap operates in the investment industry and focuses on long-term equity investments in medical technology and pharmaceutical companies. The company's portfolio includes companies in sectors such as biotechnology and medical technology. The operations are primarily concentrated in Sweden, with a primary presence in the Stockholm region. MedCap was founded in 2001 and is headquartered in Stockholm.

Read more
Market cap
7.84B SEK
Turnover
5.84M SEK
Revenue
1.81B
EBIT %
15.07 %
P/E
37.21
Dividend yield-%
-
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6.2
2026

Annual report '25

29.4
2026

Interim report Q1'26

21.7
2026

Interim report Q2'26

All
Press releases
3rd party
ShowingAll content types
Press release10/27/2025, 1:26 PM

Redeye: MedCap (Q3 review) - Healthy Q3 figures

MedCap
Regulatory press release10/24/2025, 4:30 AM

MedCap AB: Strong organic and acquired growth; EBITA increased by 32%

MedCap
Regulatory press release10/1/2025, 1:00 PM

MedCap AB: Abilia acquires LivAssured

MedCap

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release7/23/2025, 12:05 PM

Redeye: MedCap Q2 2025 - The rise, fall, and rise again

MedCap
Regulatory press release7/23/2025, 4:30 AM

MedCap AB: Strong quarter with 20 percent EBITA growth and acquisition in Specialty Pharma

MedCap
Regulatory press release7/21/2025, 10:00 AM

MedCap AB: MedCap's Business Area Specialty Pharma Completes the Acquisition of XGX Pharma

MedCap
Regulatory press release6/25/2025, 5:30 AM

MedCap AB: MedCap's Business Area Specialty Pharma Acquires XGX Pharma

MedCap
Press release4/30/2025, 5:47 AM

Redeye: MedCap Q1 2025 - Step by step

MedCap
Regulatory press release4/29/2025, 4:30 AM

MedCap AB: 7% growth and EBITA margin recovers to 17%

MedCap
Press release2/3/2025, 7:53 AM

Redeye: MedCap Q4 2024 - A tale of euphoria and despair

MedCap
Regulatory press release1/31/2025, 5:30 AM

MedCap AB: Good demand but unsatisfactory earnings. Strong cash flow.

MedCap
Regulatory press release1/31/2025, 5:30 AM

MedCap AB: MedCap's Business Area Assistive Tech Acquires Danrehab

MedCap
Regulatory press release1/16/2025, 5:30 PM

MedCap AB: Preliminary result for the fourth quarter

MedCap
Press release11/4/2024, 9:24 AM

Redeye: Redeye Initiates Coverage of MedCap

MedCap
Regulatory press release10/25/2024, 4:30 AM

MedCap AB: Profit growth, stronger cash flow and acquisitions

MedCap
Regulatory press release7/24/2024, 4:30 AM

MedCap AB: Continued strong growth - adjusted EBITA increased by 13 percent

MedCap
Regulatory press release7/24/2024, 4:30 AM

MedCap AB: Abilia acquires Picomed and Alert-IT

MedCap
Press release7/12/2024, 8:00 AM

MedCap AB: Changed date for the release of MedCap's half-year report 2024

MedCap
Regulatory press release5/3/2024, 4:30 AM

MedCap AB: Strong first quarter - EBITA up 46 percent

MedCap
Press release3/25/2024, 2:45 PM

MedCap AB: Abilia acquires Kompany AS and the product Komp

MedCap
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.